NEW YORK (GenomeWeb) – Transgenomic today announced that it has non-exclusively licensed its portfolio of intellectual property related to DNA susceptibility testing for long QT syndrome to Laboratory Corporation of America.
Long QT syndrome is a primarily congenital heart rhythm disorder associated with cardiac arrhythmia and can be triggered by prescription medicines in individuals prone to the condition.
Transgenomic said that it is eligible to receive royalties under the licensing arrangement. Additional terms were not disclosed.
"The portfolio includes relevant intellectual property from a number of major research and commercial institutions, and we believe it produces more comprehensive and accurate test results," Transgenomic President and CEO Paul Kinnon said in a statement. "LabCorp has the scale and reach to ensure that this superior LQTS testing is broadly available to patients who might benefit, with the potential to reduce the burden of this dangerous condition and improve overall patient care."
The deal with LabCorp marks the latest in a string of agreements Transgenomic has signed recently for its non-core assets as it focuses on its ICE-COLD PCR molecular diagnostics technology.
It divested its Surveyor Nuclease technology in 2014, and its ion chromatography business and Genetic Assays and Platforms unit in 2015. And earlier this year, it halted operations at its Connecticut-based patient testing laboratory while it considers strategic alternatives for the facility.